Your Name]
Your Position/Title]
Institution Name]
Address]
Email Address]
Phone Number]
Date]
The Chairperson
nstitutional Ethics Committee
Institution/Hospital Name]
Address]
Subject: Ethics Committee Submission for the Study Titled
Efficacy, Safety and Tolerability of Tofacitinib for Treatment of Polyarticular Course Juvenile
diopathic Arthritis (JIA) in Children and Adolescent Subjects"
Dear Sir/Madam,
am pleased to submit, for your kind review and approval, the protocol and related documents for
he above-mentioned clinical study. The study is designed to evaluate the efficacy, safety, and
colorability of Tofacitinib in the treatment of polyarticular course. Luvenile Idionathic Arthritic (IIA) in

This study aims to address the unmet therapeutic need in this vulnerable population by exploring an oral targeted therapy that may offer significant clinical benefit. The study will be conducted in

children and adolescents.

compliance with the ICH-GCP guidelines, applicable regulatory requirements, and institutional ethical standards.

Please find enclosed the following documents for your review:

- Study Protocol
- Informed Consent and Assent Forms
- Investigator's Brochure
- Case Report Forms (if applicable)
- CV of the Principal Investigator
- Site Feasibility Questionnaire (if applicable)
- Other required documents as per the IEC submission checklist

We assure you that participant safety and ethical conduct will be of utmost priority throughout the study. We respectfully request your review and approval of this submission at your earliest convenience.

Thank you for your time and consideration. Please feel free to contact me for any further information or clarification.

Yours sincerely,

[Your Full Name]

[Designation, Department]

[Institution Name]